Drug Regulatory Authority of Pakistan (DRAP) completed a survey of 500 medicines, and the report will be published within the next two weeks.
DRAP officials said that before this, a survey was conducted for 100 branded medicines.
They said that after deregulations, an increase in medicine prices will be determined after the results of the survey.
Earlier on March 29, 2026, the Drug Regulatory Authority of Pakistan dismissed reports of price hikes in essential medicines across the country, stating that the rates have not “undergone any upward revision”.
The statement comes as stakeholders in recent news reports alleged that an unprecedented increase in medicine prices had been observed since February 2024.
Pakistan Drug Lawyers Forum President Noor Muhammad Mehr, a day earlier, told Dawn that the price of the insulin delivery device HumaPen Ergo II had increased by 114 per cent
The Pakistan Pharmaceutical Manufacturers Association (PPMA), however, claimed that the prices of essential medicines had remained unchanged despite a more than 20 per cent rise in fuel prices.
In its statement, Drap said that it “strongly refutes the factually incorrect news reports circulating on various media channels regarding the recent increase in prices of medicines”.
The regulatory body stated that medicine supply in Pakistan remained “unaffected” by the conflict in the Middle East and subsequent sea route disruptions, as 85pc of medicines consumed in the country were “manufactured locally”.
